What is the life expectancy of someone with Cloves Syndrome?

CLOVES syndrome is a rare overgrowth condition, and while there is no single fixed life expectancy, the prognosis varies significantly based on the severity of vascular malformations and associated complications. With proactive, multidisciplinary care, many individuals with CLOVES syndrome are living into adulthood and leading meaningful lives, though regular monitoring for progressive symptoms is essential.

How does CLOVES syndrome affect long-term prognosis?

The clinical course of CLOVES syndrome is highly variable, as the condition involves a spectrum of tissue overgrowth and vascular anomalies. Life expectancy is primarily influenced by the complexity of these malformations, particularly those affecting the spine, chest, or deep venous systems. Because CLOVES syndrome is a mosaic condition—meaning it arises from a post-zygotic mutation—the distribution and intensity of symptoms differ for every patient, making it difficult to define a uniform life expectancy.

What factors influence health outcomes in CLOVES syndrome?

Management of CLOVES syndrome requires a team of specialists to address the following critical factors that impact long-term health:

• Vascular Complications: Managing the risk of deep vein thrombosis and pulmonary embolism is a priority for many patients.


• Skeletal and Spinal Integrity: Progressive scoliosis or bony overgrowth may require orthopedic intervention to maintain mobility.


• Targeted Pharmacotherapy: The use of PI3K inhibitors has revolutionized the management of CLOVES syndrome, significantly reducing the burden of overgrowth and improving quality of life.


• Systemic Involvement: Regular screening for cardiac or lymphatic issues helps mitigate secondary health risks.

Why is early intervention important for CLOVES syndrome?

Early diagnosis of CLOVES syndrome allows for the implementation of comprehensive care plans before complications become advanced. Advances in molecular diagnostics have enabled clinicians to better understand the PIK3CA-related overgrowth spectrum, leading to more personalized treatment pathways. While CLOVES syndrome remains a life-long journey, the shift toward precision medicine has greatly improved outcomes compared to previous decades, placing a greater emphasis on functional independence and quality of life.

Next steps

• Consult with a multidisciplinary team, including specialists in vascular anomalies, genetics, and orthopedics.


• Join the DiseaseMaps.org community to connect with the 7 members who share experiences living with CLOVES syndrome.


• Ask your physician about the latest clinical trials involving PI3K inhibitor therapies.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases (GARD) Information Center.


• Orphanet: Portal for rare diseases and orphan drugs.


• OMIM (Online Mendelian Inheritance in Man): Entry #612918.


• The CLOVES Syndrome Community (patient advocacy foundation).